Valuation: Delcath Systems, Inc.

Market Cap 518M 465M 425M 388M 732M 48.64B 755M 5.12B 2.04B 25.98B 1.94B 1.9B 82.06B P/E 2026 *
-93.3x
P/E 2027 * -182x
Enterprise Value 518M 465M 425M 388M 732M 48.64B 755M 5.12B 2.04B 25.98B 1.94B 1.9B 82.06B EV / Sales 2026 *
4.88x
EV / Sales 2027 * 3.93x
Free-Float
91.92%
Yield 2026 *
-
Yield 2027 * -
1 day+3.04%
1 week+6.34%
Current month+6.34%
1 month-2.93%
3 months-1.19%
6 months+32.83%
Current year+47.82%
1 week 14.03
Extreme 14.03
15.25
1 month 13.91
Extreme 13.91
15.77
Current year 8.48
Extreme 8.485
17.42
1 year 8.12
Extreme 8.12
17.42
3 years 2.25
Extreme 2.25
18.23
5 years 2.25
Extreme 2.25
18.23
10 years 2.25
Extreme 2.25
353,658,536.59
Manager TitleAgeSince
Chief Executive Officer 62 2020-09-30
Director of Finance/CFO 47 2023-04-30
Chief Operating Officer 55 2024-03-17
Director TitleAgeSince
Chairman 62 2023-02-15
Director/Board Member 70 2020-02-13
Director/Board Member 60 2020-05-05
Date Insider Type Main position Quantity % Market Cap. Importance
10/13/26
Rosalind Advisors, Inc.
ConversionCompany -36 0.3911%
10/13/26
Rosalind Advisors, Inc.
ConversionCompany 31,129 0.0897%
5/13/26 Free

Director

22,500 0.0646%
Change 5-day change 1-year change 3-year change Capi.($)
+3.04%+6.34%+72.80%+362.23% 518M
-3.23%+3.51%-13.00%+15.96% 190B
-2.90%+5.45%+10.41%+40.45% 125B
-2.75%+11.65%-8.47%+18.50% 124B
+0.96%+5.15%-37.16%+12.09% 99.31B
-1.80%+0.82%-7.52%+70.12% 63.65B
-0.78%+7.07%+19.14%-17.27% 57.71B
+0.79%+22.65%-4.57%+60.02% 53.26B
-6.98%-14.56%-11.97%+46.23% 47.03B
-2.36%+3.72%+3.86%-7.99% 36.15B
Average -1.60%+5.38%+2.35%+60.03% 79.67B
Weighted average by Cap. -2.20%+5.71%-7.43%+25.49%

Financials

2026 *2027 *
Net sales 106M 95.34M 87.06M 79.53M 150M 9.97B 155M 1.05B 419M 5.33B 399M 390M 16.82B 132M 118M 108M 98.83M 186M 12.39B 192M 1.31B 520M 6.62B 495M 485M 20.91B
Net income -6.14M -5.51M -5.03M -4.6M -8.67M -577M -8.95M -60.74M -24.2M -308M -23.05M -22.56M -973M -3.39M -3.04M -2.78M -2.54M -4.78M -318M -4.94M -33.51M -13.35M -170M -12.72M -12.44M -537M
Net Debt - -
Projected Income Statement - Annual - Delcath Systems, Inc.
Logo Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT comprises the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).
Employees
156
Date Price Change Volume
26-11-06 US$14.93 +3.04% 696,857
26-11-05 US$14.49 -2.23% 554,121
26-11-04 US$14.82 +2.92% 394,793
26-11-03 US$14.40 +0.77% 386,765
26-11-02 US$14.29 +1.78% 364,892
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Delcath Systems, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
14.93USD
Average target price
24.00USD
Spread / Average Target
+60.75%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Delcath Systems, Inc.
  1. Stock Market
  2. Stocks
  3. DCTH Stock